Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: Results from the ONSET-OFFSET and RESPOND studies

Clinical Pharmacokinetics

Volumn 51, Issue 6, 2012, Pages 397-409

  Husted, Steen E ^a   Storey, Robert F ^b   Bliden, Kevin ^c   Tantry, Udaya S ^c   Høimark, Lene ^a   Butler, Kathleen ^d   Wei, Cheryl ^d   Teng, Renli ^d   Gurbel, Paul A ^c  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c SINAI CENTER FOR THROMBOSIS RESEARCH   (United States)

^d ASTRAZENECA   (United Kingdom)

Author keywords

Acute coronary syndromes; Clopidogrel.; Pharmacokinetics; Pharmacology; Purinoceptor P2Y12 antagonists; Ticagrelor

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN II ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; NITRATE; PROTON PUMP INHIBITOR; STATIN; TICAGRELOR;

ADD ON THERAPY; ADULT; AREA UNDER THE CURVE; ARTICLE; BRADYCARDIA; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EXPOSURE; DRUG WITHDRAWAL; DYSPNEA; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMAN; HYPOTENSION; LIMIT OF QUANTITATION; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; MYALGIA; PHARMACODYNAMICS; PHARMACOKINETICS; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SLEEP DISORDER; T WAVE INVERSION; THROMBOCYTE AGGREGATION; THROMBOCYTE RICH PLASMA; TREATMENT DURATION; TREATMENT RESPONSE;

ADENOSINE; AGED; CORONARY ARTERY DISEASE; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION; PURINERGIC P2Y RECEPTOR ANTAGONISTS; TICLOPIDINE;

EID: 84860463430     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.2165/11599830-000000000-00000     Document Type: Article

References (24)

1. Springthorpe B, Bailey A, Barton P, et al. From ATP to AZD6140: the discovery of an orally active reversible P2Y12 receptor antagonist for the prevention of thrombosis. Bioorg Med Chem Lett 2007; 17: 6013-8 (Pubitemid 47446193)
2. Husted S, van Giezen JJ. Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist. Cardiovasc Ther 2009; 27: 259-74
3. Husted S, Emanuelsson H, Heptinstall S, et al. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J 2006; 27: 1038-47
4. Cannon CP, Husted S, Harrington RA, et al. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. J Am Coll Cardiol 2007; 50: 1844-51 (Pubitemid 350007959)
5. Brilique. Summary of product characteristics 2010 [online].Available fromURL: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product- Information/human/002303/WC500100584.pdf [Accessed 2011 Dec 19]
6. BrilintaTM, US full prescribing information, July 2011 [online]. Available from URL: http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/ 022433s000lbl.pdf [Accessed 2011 Dec 19]
7. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045-57
8. Teng R, Butler K. AZD6140, the first reversible oral platelet P2Y12 receptor antagonist, has linear pharmacokinetics and provides near complete inhibition of platelet aggregation, with reversibility of effect in healthy subjects [abstract no. 9]. Can J Clin Pharmacol 2008; 15: e426
9. Teng R, Butler K. Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y12 receptor antagonist in healthy subjects. Eur J Clin Pharmacol 2010; 66: 487-96
10. Butler K, Teng R. Pharmacokinetics, pharmacodynamics and safety and tolerability of multiple ascending doses of ticagrelor in healthy volunteers. Br J Clin Pharmacol 2010; 70: 65-77
11. Pereillo J-M, Maftouh M, Andrieu A, et al. Structure and stereochemistry of the active metabolite of clopidogrel. Drug Metab Dispos 2002; 30: 1288-95 (Pubitemid 35265838)
12. Dansette PM, Rosi J, Bertho G, et al. Cytochromes P450 catalyze both steps of the major pathway of clopidogrel bioactivation, whereas paraoxonase catalyzes the formation of a minor thiol metabolite isomer. Chem Res Toxicol 2012; 25 (2): 348-56
13. van Giezen JJJ, Nilsson L, Berntsson P, et al. Ticagrelor binds to human P2Y12 independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation. J Thromb Haemst 2009; 7: 1556-65
14. Teng R, Oliver S, Hayes MA, et al. Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects. Drug Metab Dispos 2010; 38: 1514-21
15. Zhou D, Andersson TB, GrimmSW. In vitro evaluation of potential drug-drug interactions with ticagrelor: cytochrome P450 reaction phenotyping, inhibition, induction and differential kinetics. Drug Metab Dispos 2011; 39: 703-10
16. Storey RF, Husted S, Harrington RA, et al. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol 2007; 50: 1852-6 (Pubitemid 350017792)
17. Gurbel PA, Bliden KP, Butler K, et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation 2009; 120: 2577-85
18. Gurbel PA, Bliden KP, Antonino M, et al. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. Circulation 2010; 121: 1188-99
19. SillénH, Cook M, Davis P. Determination of ticagrelor and two metabolites in plasma samples by liquid chromatography and mass spectrometry. J Chromatogr B 2010; 878: 2299-306
20. Gurbel PA, Bliden KP, Hiatt BL, et al. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003; 107: 2908-13 (Pubitemid 36736631)
21. Weber MA, Bakris GL, Dahlöm B, et al. Baseline characteristics in the avoiding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trial: a hypertensive population at high cardiovascular risk. Blood Press 2007; 16: 13-9 (Pubitemid 46672249)
22. Fellström BC, Jardein AG, Schmieder RE, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis.NEngl J Med 2009; 360: 1395-407
23. Steinhubl SR, Oh JJ, Oestreich JH, et al. Transitioning patients from cangrelor to clopidogrel: pharmacodynamic evidence of a competitive effect. Thromb Res 2008; 121: 527-34 (Pubitemid 351174272)
24. van Giezen JJ, Humphries RG. Preclinical and clinical studies with selective reversible direct P2Y12 antagonists. Semin Thromb Hemost 2005; 31: 195-204 (Pubitemid 40605194)